vs
CORCEPT THERAPEUTICS INC（CORT）与MARCUS CORP（MCS）财务数据对比。点击上方公司名可切换其他公司
CORCEPT THERAPEUTICS INC的季度营收约是MARCUS CORP的1.0倍（$202.1M vs $193.5M），CORCEPT THERAPEUTICS INC同比增速更快（11.1% vs 2.8%），CORCEPT THERAPEUTICS INC自由现金流更多（$38.4M vs $26.4M），过去两年MARCUS CORP的营收复合增速更高（18.2% vs 17.3%）
Corcept Therapeutics是一家制药企业，专注于严重代谢疾病、精神疾病及肿瘤疾病治疗药物的发现、开发与商业化。公司围绕皮质醇过量带来的不良影响展开研究，致力于开发可缓解相关症状的新型化合物，管理团队由首席执行官兼总裁、董事Joseph K. Belanoff医学博士领导。
马库斯公司是一家美国企业，主营商业地产领域相关服务，业务覆盖美国与加拿大，提供商业地产经纪、按揭经纪、行业研究以及咨询服务，首创了由单一经纪公司独家代理房源挂牌的行业模式，目前在美加两国设有超过80家办公室，拥有员工超1800名。
CORT vs MCS — 直观对比
营收规模更大
CORT
是对方的1.0倍
$193.5M
营收增速更快
CORT
高出8.4%
2.8%
自由现金流更多
CORT
多$12.0M
$26.4M
两年增速更快
MCS
近两年复合增速
17.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $202.1M | $193.5M |
| 净利润 | $24.3M | — |
| 毛利率 | 98.7% | — |
| 营业利润率 | 2.2% | 0.9% |
| 净利率 | 12.0% | — |
| 营收同比 | 11.1% | 2.8% |
| 净利润同比 | -21.0% | — |
| 每股收益（稀释后） | $0.20 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CORTMCS
| Q4 25 | $202.1M | $193.5M | ||
| Q3 25 | $207.6M | $210.2M | ||
| Q2 25 | $194.4M | $206.0M | ||
| Q1 25 | $157.2M | $148.8M | ||
| Q4 24 | $181.9M | $188.3M | ||
| Q3 24 | $182.5M | $232.7M | ||
| Q2 24 | $163.8M | $176.0M | ||
| Q1 24 | $146.8M | $138.5M |
净利润CORTMCS
| Q4 25 | $24.3M | — | ||
| Q3 25 | $19.7M | $16.2M | ||
| Q2 25 | $35.1M | $7.3M | ||
| Q1 25 | $20.5M | $-16.8M | ||
| Q4 24 | $30.7M | $986.0K | ||
| Q3 24 | $47.2M | $23.3M | ||
| Q2 24 | $35.5M | $-20.2M | ||
| Q1 24 | $27.8M | $-11.9M |
毛利率CORTMCS
| Q4 25 | 98.7% | — | ||
| Q3 25 | 97.8% | — | ||
| Q2 25 | 98.2% | — | ||
| Q1 25 | 98.5% | — | ||
| Q4 24 | 98.4% | — | ||
| Q3 24 | 98.4% | — | ||
| Q2 24 | 98.5% | — | ||
| Q1 24 | 98.3% | — |
营业利润率CORTMCS
| Q4 25 | 2.2% | 0.9% | ||
| Q3 25 | 4.9% | 10.8% | ||
| Q2 25 | 13.7% | 6.3% | ||
| Q1 25 | 2.2% | -13.7% | ||
| Q4 24 | 13.9% | -1.2% | ||
| Q3 24 | 25.5% | 14.1% | ||
| Q2 24 | 21.7% | 1.3% | ||
| Q1 24 | 20.1% | -12.0% |
净利率CORTMCS
| Q4 25 | 12.0% | — | ||
| Q3 25 | 9.5% | 7.7% | ||
| Q2 25 | 18.1% | 3.6% | ||
| Q1 25 | 13.1% | -11.3% | ||
| Q4 24 | 16.9% | 0.5% | ||
| Q3 24 | 25.9% | 10.0% | ||
| Q2 24 | 21.7% | -11.5% | ||
| Q1 24 | 18.9% | -8.6% |
每股收益（稀释后）CORTMCS
| Q4 25 | $0.20 | — | ||
| Q3 25 | $0.16 | — | ||
| Q2 25 | $0.29 | — | ||
| Q1 25 | $0.17 | — | ||
| Q4 24 | $0.25 | — | ||
| Q3 24 | $0.41 | — | ||
| Q2 24 | $0.32 | — | ||
| Q1 24 | $0.25 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $372.2M | $23.4M |
| 总债务越低越好 | — | $159.0M |
| 股东权益账面价值 | $647.8M | $457.4M |
| 总资产 | $836.7M | $1.0B |
| 负债/权益比越低杠杆越低 | — | 0.35× |
8季度趋势，按日历期对齐
现金及短期投资CORTMCS
| Q4 25 | $372.2M | $23.4M | ||
| Q3 25 | $421.7M | $7.4M | ||
| Q2 25 | $342.2M | $14.9M | ||
| Q1 25 | $322.8M | $11.9M | ||
| Q4 24 | $383.3M | $40.8M | ||
| Q3 24 | $380.3M | $28.4M | ||
| Q2 24 | $473.2M | $32.8M | ||
| Q1 24 | $410.8M | $17.3M |
总债务CORTMCS
| Q4 25 | — | $159.0M | ||
| Q3 25 | — | $162.0M | ||
| Q2 25 | — | $179.9M | ||
| Q1 25 | — | $198.9M | ||
| Q4 24 | — | $159.1M | ||
| Q3 24 | — | $173.1M | ||
| Q2 24 | — | $175.7M | ||
| Q1 24 | — | $169.8M |
股东权益CORTMCS
| Q4 25 | $647.8M | $457.4M | ||
| Q3 25 | $631.9M | $454.3M | ||
| Q2 25 | $635.8M | $448.4M | ||
| Q1 25 | $683.3M | $441.8M | ||
| Q4 24 | $679.6M | $464.9M | ||
| Q3 24 | $638.8M | $462.3M | ||
| Q2 24 | $596.2M | $449.4M | ||
| Q1 24 | $547.9M | $459.3M |
总资产CORTMCS
| Q4 25 | $836.7M | $1.0B | ||
| Q3 25 | $823.6M | $1.0B | ||
| Q2 25 | $801.7M | $1.0B | ||
| Q1 25 | $846.5M | $1.0B | ||
| Q4 24 | $840.6M | $1.0B | ||
| Q3 24 | $784.3M | $1.0B | ||
| Q2 24 | $714.6M | $1.1B | ||
| Q1 24 | $655.9M | $1.0B |
负债/权益比CORTMCS
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.34× | ||
| Q3 24 | — | 0.37× | ||
| Q2 24 | — | 0.39× | ||
| Q1 24 | — | 0.37× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $38.4M | $48.8M |
| 自由现金流经营现金流 - 资本支出 | $38.4M | $26.4M |
| 自由现金流率自由现金流/营收 | 19.0% | 13.6% |
| 资本支出强度资本支出/营收 | 0.0% | 11.6% |
| 现金转化率经营现金流/净利润 | 1.58× | — |
| 过去12个月自由现金流最近4个季度 | — | $989.0K |
8季度趋势，按日历期对齐
经营现金流CORTMCS
| Q4 25 | $38.4M | $48.8M | ||
| Q3 25 | $54.5M | $39.1M | ||
| Q2 25 | $43.9M | $31.6M | ||
| Q1 25 | $5.1M | $-35.3M | ||
| Q4 24 | $59.3M | $52.6M | ||
| Q3 24 | $73.8M | $30.5M | ||
| Q2 24 | $41.2M | $36.0M | ||
| Q1 24 | $23.8M | $-15.1M |
自由现金流CORTMCS
| Q4 25 | $38.4M | $26.4M | ||
| Q3 25 | — | $18.2M | ||
| Q2 25 | $43.9M | $14.7M | ||
| Q1 25 | $5.0M | $-58.3M | ||
| Q4 24 | $59.2M | $27.1M | ||
| Q3 24 | $72.2M | $12.0M | ||
| Q2 24 | $40.8M | $16.1M | ||
| Q1 24 | — | $-30.5M |
自由现金流率CORTMCS
| Q4 25 | 19.0% | 13.6% | ||
| Q3 25 | — | 8.7% | ||
| Q2 25 | 22.6% | 7.1% | ||
| Q1 25 | 3.2% | -39.2% | ||
| Q4 24 | 32.5% | 14.4% | ||
| Q3 24 | 39.5% | 5.2% | ||
| Q2 24 | 24.9% | 9.2% | ||
| Q1 24 | — | -22.0% |
资本支出强度CORTMCS
| Q4 25 | 0.0% | 11.6% | ||
| Q3 25 | 0.0% | 9.9% | ||
| Q2 25 | 0.0% | 8.2% | ||
| Q1 25 | 0.1% | 15.5% | ||
| Q4 24 | 0.1% | 13.5% | ||
| Q3 24 | 0.9% | 7.9% | ||
| Q2 24 | 0.3% | 11.3% | ||
| Q1 24 | 0.0% | 11.1% |
现金转化率CORTMCS
| Q4 25 | 1.58× | — | ||
| Q3 25 | 2.77× | 2.41× | ||
| Q2 25 | 1.25× | 4.32× | ||
| Q1 25 | 0.25× | — | ||
| Q4 24 | 1.93× | 53.31× | ||
| Q3 24 | 1.56× | 1.31× | ||
| Q2 24 | 1.16× | — | ||
| Q1 24 | 0.86× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CORT
暂无分部数据
MCS
| Theatres | $123.1M | 64% |
| Concessions | $51.0M | 26% |
| Food And Beverage | $21.2M | 11% |
